• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Can One Year DM1 Data Change The Bull Case For Dyne Therapeutics Stock?

    Simply Wall St·10/13/2026 11:28:30
    Listen to the news
    • Dyne Therapeutics reported additional one year data from the Phase 1/2 ACHIEVE trial of z basivarsen in DM1, with sustained improvements across myotonia, function, strength and patient reported outcomes, along with a favorable safety profile compared with natural history cohorts.
    • The mixed dose exposures in the pooled group and the alignment of key ACHIEVE and HARMONIA endpoints with potential accelerated and traditional approvals provide investors with clearer insight into how Dyne Therapeutics is designing a path from early clinical signals toward potential long term commercial use in DM1.
    • We will now examine how Dyne Therapeutics' investment narrative could be influenced by sustained one year functional gains in DM1.
    Spot 20 high quality undiscovered gems pursuing similarly ambitious treatments, so you can compare Dyne Therapeutics' DM1 story with other under the radar healthcare opportunities.

    Dyne Therapeutics Investment Narrative Recap

    To own Dyne Therapeutics, you need to believe this is a rare disease platform that can turn the recent DM1 signal, the DMD franchise and a broad FORCE pipeline into approved products while managing heavy R&D and no current revenue. The new one year ACHIEVE data supports that thesis but does not remove the binary nature of upcoming readouts.

    The key near term catalyst still sits with ACHIEVE REC vHOT data in early 2027 and the HARMONIA 5xSTS outcome that follows. The biggest risk remains that z basivarsen fails to show a persuasive effect on those registrational endpoints, which could leave Dyne Therapeutics with high spend, shareholder dilution and a longer road to meaningful sales.

    The clearest link between this update and the catalyst stack is the accepted BLA with Priority Review for z rostudirsen in exon 51 DMD, which carries a January 21, 2027 PDUFA date. That filing shows Dyne Therapeutics already interacting with regulators on another FORCE asset while z basivarsen advances, creating parallel shots on goal.

    If z rostudirsen reaches the market and the broader DMD exon skipping portfolio expands as planned, any DM1 approval would slot into an existing commercial footprint instead of requiring a fresh build out. That operational overlap, combined with the recent equity raise and cash plus term loan capacity, gives the group time to execute but also extends exposure to regulatory and execution risk.

    What The Dyne Therapeutics Forecasts Really Assume

    Dyne Therapeutics' long term story is tied directly to some punchy analyst math. Forecasts point to revenue of US$472.1 million by 2029, off a base of zero today. That profile reflects a shift from pure R&D vehicle to fully commercial business if the pipeline clears regulatory hurdles.

    Profit expectations embed an equally sharp turn. Analysts map earnings moving from a loss of US$519.4 million today to a profit of US$81.4 million in 2029, using a 17.2% profit margin that matches the current average for US biotech peers. That swing of US$600.8 million in earnings is what underpins the use of a 126.3x future P/E multiple on those projected 2029 profits.

    The valuation overlay is demanding. To line up with the US$36.0 analyst target, investors would have to accept Dyne Therapeutics at that 126.3x P/E on 2029 earnings, which is above the 17.1x P/E cited for the broader US biotech group. The gap between those multiples illustrates how much success in DM1 and DMD is already embedded in the long range numbers.

    Share count assumptions matter as well. Consensus figures build in 7.0% yearly growth in shares outstanding over the next three years, reflecting ongoing capital needs as late stage studies, regulatory work and commercial build out progress. Any additional equity raises beyond that could dilute per share earnings relative to the headline profit estimate.

    Dyne Therapeutics' narrative projects US$472.1 million in revenue and US$81.4 million in earnings by 2029. This implies very rapid yearly revenue growth from zero today and a US$600.8 million earnings increase from a loss of US$519.4 million.

    Discover why Dyne Therapeutics' fair value suggests a 126% potential upside to its current price, which could narrow quickly.

    NasdaqGS:DYN 1-Year Stock Price Chart
    NasdaqGS:DYN 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate story around Dyne Therapeutics leans hard into DM1 risk. The most bearish analysts were only penciling in about US$222.0 million of 2029 revenue and US$38.2 million of earnings before this new one year ACHIEVE update. That is a much more cautious path. Use it as a reference point while you compare different views.

    Explore 4 other Dyne Therapeutics fair value estimates, including one that suggests it could be worth just $16.12.

    Reach Your Own Conclusion

    Don't just follow the ticker; dig into the data and build a conviction that's truly your own.

    Looking For More Investment Ideas Beyond Dyne Therapeutics?

    If Dyne Therapeutics has sharpened your interest in high conviction stories, consider broadening your watchlist with a few targeted stock lists that match different risk and income preferences.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.